openPR Logo
Press release

The Acquired Hemolytic Anemia market to witness an incremental CAGR between 2020 and 2030

Hemolytic anemia is a diseased condition characterized by premature destruction of red blood cells (RBCs) and their removal from the blood circulatory system before their life span is over. Red blood cells also known as erythrocytes are disk like structures that carry oxygen from lungs to body organs and help in removing carbon dioxide from the body. Usually red blood cells (RBCs) have a normal life span of 120 before they are removed from the blood stream by spleen. Red blood cells are produced by bone marrow. In people suffering from acquired (autoimmune) hemolytic anemia, bone marrows are unable to produce enough RBCs to meet body’s demand.

For more insights into the Market, request a sample of this report @ https://www.persistencemarketresearch.com/samples/19732

Acquired (autoimmune) hemolytic anemia is non-genetic in nature and usually occurs when the body’s own immune system destroys its healthy tissues against invading organisms such as lymphocytes and antibodies. Acquired (autoimmune) hemolytic anemia generally occurs as a result or in conjunction with some other medical conditions. This condition rarely occurs alone. Acquired (autoimmune) hemolytic anemia can be classified as warm antibody hemolytic anemia and cold antibody hemolytic anemia. In warm antibody hemolytic anemia, auto-antibodies attach with the red blood cells and kill them at temperature higher than the body temperature; conversely, in cold antibody hemolytic anemia self-generated antibodies kill red blood cells at a temperature below the body temperature.

For Information On The Research Methodology request here @ https://www.persistencemarketresearch.com/methodology/19732

Diagnosis involves a range of blood tests such as hemoglobin and hematocrit test, bilirubin test, serum haptoglobin test and reticulocyte count. If the ratio is high, there is likeliness of hemolytic anemia. Coombs test is another key diagnostic method for acquired (autoimmune) hemolytic anemia in which the amount of certain antibodies is determined in order to check if it is higher than normal. Treatment is based on three major aims, preventing the destruction of RBCs, increasing the RBCs count and treating the origin of illness. Blood transfusion, medications, plasmapheresis and surgeries are among major treatment options. Prednisone, rituximab, hydroxyurea and cyclosporine are some drugs that are usually prescribed for treating acquired (autoimmune) hemolytic anemia.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/19732

There are no exact incidence and prevalence statistics are available regarding the acquired (autoimmune) hemolytic anemia. According to sources from Elsevier, Inc. the incidence rate of all types of acquired (autoimmune) hemolytic anemias range from one new case per 100,000 general population to 300,000 per year. Though the prevalence is not so high, severity of the condition will play a key role in driving the market growth. The market will also be driven by unmet medical needs as there is no standard medicines available for treating acquired hemolytic anemia. Many companies are conducting clinical trials in order to introduce effective medicines for acquired hemolytic anemia. Some major pharmaceutical companies and research institutions that are engaged in the development, manufacturing and marketing of drugs for this market include Novartis AG, Sanofi, Centre Hospitalier Universitaire Dijon, Institute of Hematology & Blood Diseases Hospital, Hoffmann-La Roche, National Cancer Institute (NCI), Agios Pharmaceuticals, Inc., Octapharma Pharmazeutika Produktionsges.m.b.H., National Heart, Lung, and Blood Institute (NHLBI) and Baxter Healthcare Corporation.

Geographically, the acquired (autoimmune) hemolytic anemia market has been segmented into North America, Europe, Asia-Pacific and Rest of the World (RoW). Globally, the market is led by North America, followed by Europe, Asia-Pacific and Rest of the World (RoW). High level of awareness, high per capita income and well established reimbursement scenario are among the major factors responsible for North America’s leading position in the acquired (autoimmune) hemolytic anemia market.

Contact Us:
305 Broadway
7th Floor
New York City, NY 10007
United States
U.S.A - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com

Persistence Market Research (PMR) is an innovative and specialized publisher of market intelligence reports and consulting services. Prompt delivery, in-depth research, and high quality are the sacrosanct principles of PersistenceMarketResearch.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Acquired Hemolytic Anemia market to witness an incremental CAGR between 2020 and 2030 here

News-ID: 2203427 • Views:

More Releases from Persistence Market Research

North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and
Global Forged Automotive Components Market Poised for Steady Growth, Projected to Reach US$ 70.7 Billion by 2032
Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts. Forged automotive components are critical to
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ 2.14 Billion by 2032, Reports Persistence Market Research
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Driven by Urbanization and Demographic Trends
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring

All 5 Releases


More Releases for RBCs

Creative Diagnostics Introduces New Anti-RBC Antibodies for Enhanced Blood Produ …
Creative Diagnostics launches Anti-RBC antibodies for impurity cleansing of blood products and the diagnosis of RBC-affected autoimmune diseases. Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, announces the launch of its new line of Anti-RBC antibodies [https://www.creative-diagnostics.com/anti-rbc-antibodies-for-impurity-cleansing-and-research-of-rbcs-affected-autoimmune-diseases-diagnosis.htm] for impurity cleansing of blood products and the diagnosis of RBC-affected autoimmune diseases. These innovative products offer exceptional performance and can be used in a variety of scientific applications,
Creative Diagnostics Launches Reliable Hemagglutination Assay for Virus and Anti …
Creative Diagnostics launches Hemagglutination Assay services for effective virus and antibody detection. As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its Hemagglutination Assay [https://antiviral.creative-diagnostics.com/hemagglutination-assay-ha.html] (HA) services for effective virus and antibody detection. The new anti-virus testing solution offers a valuable tool for researchers working on influenza virus characterization, vaccine development, and general viral diagnostics. Certain viruses agglutinate red blood
Gel Card Tests Market Revenue, Insights, Overview, Outlook, Analysis | Valuates …
Gel Card Tests Market A gel card test, also known as a gel agglutination test, is a type of diagnostic test used in immunohematology to determine blood compatibility, blood group typing, and the presence of specific antibodies in blood samples. Gel card tests utilize gel matrix technology to simplify and expedite the process of performing multiple blood tests simultaneously in a single platform. According to new survey, global Gel Card Tests market
Acquired (Autoimmune) Hemolytic Anemia Market Novartis, Sanofi, Hoffmann-La Roch …
Hemolytic anemia is a diseased condition characterized by premature destruction of red blood cells (RBCs) and their removal from the blood circulatory system before their life span is over. Red blood cells also known as erythrocytes are disk like structures that carry oxygen from lungs to body organs and help in removing carbon dioxide from the body. Usually red blood cells (RBCs) have a normal life span of 120 before
Complete Blood Count (CBC) Market Analysis Reveals explosive growth by 2023 | An …
The demand for Complete Blood Count (CBC) Market is anticipated to be high for the next few years. By considering this demand we provide latest Complete Blood Count (CBC) Market Report which gives complete industry analysis, market outlook, size, growth and forecast till 2023. This report will assist in analyzing the current and future business trends, sales and revenue forecasts. Global Complete Blood Count (CBC) Market Overview: This report studies the Global
Nanobots Pave Way For The Development Of Artificial Antibodies, Artificial RBCs …
The emerging technology of nanobots offers better chances of fighting chronic diseases such as cancer. Moreover, further developments in nanomedicine market can create opportunities such as the development of artificial antibodies and artificial RBCs and WBCs. Nanomedicine is a domain of medicine that utilizes the knowledge of nanotechnology to prevent and treat severe diseases such as cancer and heart diseases. The recent advances in nanotechnology have enabled doctors to use